However, by CRISPR-Cas system knockout, the angiogenesis driven by exosome-borne ANGPT2 could be significantly inhibited, and the activation of epithelial-mesenchymal transition (EMT) in HCC can also be suppressed (18). The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.